بدائل البحث:
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
inter decrease » linear decrease (توسيع البحث), water decreases (توسيع البحث), teer decrease (توسيع البحث)
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
inter decrease » linear decrease (توسيع البحث), water decreases (توسيع البحث), teer decrease (توسيع البحث)
-
1661
-
1662
-
1663
-
1664
-
1665
-
1666
-
1667
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
منشور في 2024الموضوعات: -
1668
-
1669
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1670
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1671
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1672
-
1673
-
1674
-
1675
-
1676
-
1677
-
1678
-
1679
-
1680